Chromosomal Rearrangement of the PAX-5 Locus in Lymphoplasmacytic Lymphoma with t(9; 14) (p13; q32)

Leukemia and Lymphoma

Volumn 34, Issue 42006, 1999, Pages 25-33

  Iida, Shinsuke ^a,b   Rao, Pulivarthi H ^c   Ueda, Ryuzo ^b   Chaganti, R S K ^c   Dalla Favera, Riccardo ^a  

^a Columbia University ^*  (United States)

^b NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

BSAP; chromosomal translocation; lymphoplasmacytic lymphoma (LPL); PAX 5; t(9; 14) (p13; q32)

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; MESSENGER RNA; TRANSCRIPTION FACTOR;

B CELL LYMPHOMA; B LYMPHOCYTE; CARCINOGENESIS; CELL DIFFERENTIATION; CHROMOSOME 14Q; CHROMOSOME 9P; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; DEREGULATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; HISTOLOGY; HUMAN; IMMUNOGLOBULIN GENE; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPHOCYTE PROLIFERATION; LYMPHOMA; MESSENGER RNA SYNTHESIS; MOLECULAR BIOLOGY; NONHODGKIN LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW;

ANIMALS; B-CELL-SPECIFIC ACTIVATOR PROTEIN; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 9; DNA-BINDING PROTEINS; GENE REARRANGEMENT; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, SMALL LYMPHOCYTIC; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 0345620785     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428199909083377     Document Type: Article

References (51)

1. Rabbitts T. H. Chromosomal translocations in human cancer. Nature 1994; 372: 143 – 149
2. Gaidano G., Dalla-Favera R. Molecular biology of lymphomas. Principles and Practice of Oncology, Fifth Ed, V T DeVita, S Hellman, SA Rosenberg. JB Lippencott Co. 1997; 2131 – 2144
3. Dalla-Favera R., Bregni M., Erickson D., Patterson D., Gallo R. C., Croce C. M. Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982; 79: 7824 – 7827
4. Bakhshi A., Jensen J. P., Goldman P., Wright J. J., McBride O. W., Epstein A. L., Korsmeyer S. J. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985; 41: 889 – 906
5. Cleary M. L., Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad. Sci USA 1985; 82: 7439 – 7443
6. Tsujimoto Y., Yunis J., Onorato-Showe L., Erikson J., Nowell P. C., Croce C. M. Molecular cloning of chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science 1984; 224: 1403 – 1406
7. Motokura T., Bloom T., Kim H. G., Juppner H., Ruderman J. V., Kronenberg H. M., Arnold A. A novel cyclin encoded by a bcl-1 linked candidate oncogene. Nature 1991; 350: 512 – 515
8. Ye B. H., Lista E, Lo Coco E, Knowles D. M., Offit K, Chaganti R. S. K., Dalla-Favera R. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 1993; 262: 747 – 750
9. Gaidano G., Ballerini P., Gong J. Z., Inghirami G., Neri A., Newcomb E. W., Magrath I. T., Knowles D. M., Dalla-Favera R. p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1991; 88: 5413 – 5417
10. Lo Coco E, Gaidano G., Louie D. C., Offit K., Chaganti RS., Dalla-Favera R. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993; 82: 2289 – 2295
11. Gaidano G., Hauptschein R. S., Parsa N. Z., Offit K., Rao PH., Lenoir G., Knowles D. M., Chaganti R. S.K., Dalla-Favera R. Deletions involving two distinct regions of 6q in B-cell non-Hodgikin's lymphoma. Blood 1992; 80: 1781 – 1787
12. Iida S., Rao P. H., Nallasivam P., Hibshoosh H., Butler M, Louie D. C., Dyomin V., Ohno H., Chaganti R. S. K., Dalla-Favera R. The t(9;14)(p25;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood 1996; 88: 4110 – 4117
13. Harris N. L., Jaff E. S., Stein H., Banks P. M., Chan J. K. C., Cleary M. L., Delsol G., Wolf-Peeters C. D., Falini B., Gatter K. C., Grogan T. M., Isaacson P. G., Knowles D. M., Mason D. Y., Muller-Hermelink H-K., Pileri S. A., Piris M. A., Ralfkiger E., Warnke R. A. A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood 1993; 84: 1361 – 1392
14. Offit K., Parsa N. Z., Filippa D., Jhanwar S. C., Chaganti R. S. K. t(9;14)(p13;q32) denotes a subset of low-grade non-Hodgkin's lymphoma with plasmacytoid differentiation. Blood 1992; 80: 2594 – 2599
15. Offit K, Parsa N. Z., Jhanwar S. C., Filippa D., Wachell M., Chaganti R. S. K. Clusters of chromosome 9 aberrations are associated with clinico-pathologic subsets of non-Hodgkin's lymphoma. Genes Chromsom Cancer 1993; 7: 1 – 7
16. Ohno H., Furukawa T., Fukuhara S., Zong S. Q., Kamesaki H., Shows T. B., Le Beau M. M., McKeithan T. W., Kawakami T., Honjo T. Molecular analysis of a chromosomal translocation, t(9;14)(p13;q32), in a diffuse large-cell lymphoma cell line expressing the Ki-1 antigen. Proc Natl Acad Sci USA 1990; 87: 628 – 632
17. Busslinger M., Klix N., Pfeffer P., Graninger P. G., Kozmik Z. Deregulation of PAX-5 by translocation of the Eμ enhancer of the IgH locus adjacent to two alternative PAX 5 promoters in a diffuse large-cell lymphoma. Proc Natl Acad Sci USA 1996; 93: 6129 – 6134
18. Pellet P., Berger R., Bernheim A., Brouet J. C., Tsapis A. Molecular analysis of a t(9;14)(p11;q32) translocation occurring in a case of human alpha heavy chain disease. Oncogene 1989; 4: 653 – 657
19. Withers D. A., Harvey R. C., Faust J. B., Melnyk O., Carey K., Meeker T. C. Characterization of a candidate bcl-1 gene. Mol Cell Biol 1991; 11: 4846 – 4853
20. Seto M., Jaeger U., Hockett R. D., Graninger W., Bennett S., Goldman P., Korsmeyer S. J. Alternative promotors and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBOJ 1988; 7: 123 – 131
21. Pelicci P-G., Knowles D. M., Magrath I., Dalla-Favera R. Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma. Proc Natl Acad Sci USA 1986; 83: 2984 – 2988
22. Madisen L., Groudine M. Identification of a locus control region in the immunoglobulin heavy-chain locus that regulates c-myc expression in plasmacytoma and Burkitt's lymphoma cells. Genes Dev 1994; 8: 2212 – 2226
23. Adams B., Dorfer P., Aguzzi A., Kozmik Z., Urabanek P., Maurer-Fogy I., Busslinger M. Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testis. Genes Dev 1992; 6: 1589 – 1607
24. Urbanek P., Wang Z-Q., Fetka I., Wagner E. F., Busslinger M. Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5/BSAP. Cell 1994; 79: 901 – 912
25. Stuart E. T., Grass P. PAX genes: what's new in developmental biology and cancer. Hum Mol Genet 1995; 4: 1717 – 1720
26. Baker S. J., Reddy E. P. B cell differentiation: role of E2A and Pax5/BSAP transcription factors. Oncogene 1995; 11: 413 – 426
27. Bain G., Robanus Maandag E. C., Izon D. J., Amsen D., Kruisbeek A. M., Weintraub B. C., Krop I., Schlissel M. S., Feeney A. J., Van Roon M., Van der Valk M., Te Riele H. P. J., Berns A., Murre C. E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements. Cell 1994; 79: 885 – 892
28. Czerny T., Schaffner G., Busslinger M. DNA sequence recognition by Pax proteins: bipartite structure of the paired domain and its binding site. Genes Dev 1993; 7: 2048 – 2061
29. Dorfler P., Busslinger M. C-terminal activating and inhibitory domains determine the transactivation potential of BSAP (Pax-5), Pax-2 and Pax-8. EMBO J 1996; 15: 1971 – 1982
30. Michaelson J. S., Singh M., Birshtein B. K. B cell lineagespecific activator protein (BSAP): A player at multiple stages of B cell development. J Immunol 1996; 156: 2349 – 2351
31. Desiderio S. Transcription factors controlling B-cell development. Curr Biol 1995; 5: 605 – 608
32. Kozmik Z., Wang S., Dorfler P., Adams B., Busslinger M. The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. Mol Cel Biol 1992; 12: 2662 – 2672
33. Neurath M. R, Stuber E. R., Strober W. BSAP: a key regulator of B-cell development and differentiation. Immunol Today 1995; 16: 564 – 569
34. Zwollo P., Desiderio S. Specific recognition of the blkpromoter by the B-lymphoid transcription factor B-cell-specific activator protein. J Biol Chem 1994; 269: 15310 – 15317
35. Liao R, Birshtein Busslinger B. K. M., Rothman P. The transcription factor BSAP (NF-HB) is essential for immunoglobulin germ-line epsilon transcription. J Immunol 1994; 148: 2904 – 2911
36. Neurath M. F., Max E. E., Strober W. Pax5 (BSAP) regulates the murine immunoglobulin 3′ α enhancer by suppressing binding of NF-αP, a protein that controls heavy chain transcription. Proc Natl Acad Sci USA 1995; 92: 5336 – 5340
37. Singh M, Birshtein B. K. NF-HB (BSAP) is a repressor of the murine immunoglobulin heavy-chain 3′ α enhancer at early stages of B-cell differentiation. Mol Cell Biol 1993; 13: 3611 – 3622
38. Rinkenberger J. L., Wallin J. J., Johnson K. W., Koshland M. E. An interleukin-2 signal relieves BSAP(Pax-5)-mediated repression of the immunoglobulin J chain gene. Immunity 1996; 5: 377 – 386
39. Tian J., Okabe T., Miyazaki T., Takeshita S., Kudo A. Pax-5 is identical to EBB/KLP and binds to the Vpreß and lambda 5 promoters as well as the KI and KII sites upstream of the J kappa genes. Em J Immunol 1997; 27 (3) 750 – 755
40. Maulbecker C. C., Grass P. The oncogenic potential of Pax genes. EMBO J 1993; 12: 2361 – 2367
41. Read A. P. Pax-genes-Paired feet in three camps. Nat Genet 1996; 9: 333 – 334
42. Galili N., Davis R. J., Fredericks W. J., Mukhopadhyay S., Rauscher I II F. J., Emanuel B. S., Rovera G., Barr F. G. Fusion of a fork head domain gene to PAX-3 in the solid tumor alveolar rhabdomyosarcoma. Nature Genet 1993; 5: 230 – 235
43. Davis R. J., D'Cruz C. M., Lovell M. A., Biegel J. A., Barr F. G. Fusion of PAX-7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 1994; 54: 2869 – 2872
44. Scheidler S., Fredericks W. J., Rauscher I II F. J., Barr F. G., Vogt P. K. The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture. Proc Natl Acad Sci USA 1996; 93: 9805 – 9809
45. Bernasconi M., Remppis A., Fredericks W. J., Rauscher I II, Schafer B. W. Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc Natl Acad Sci USA 1996; 93: 13164 – 13169
46. Sublett J. E., Jeon I-S., Shapiro D. N. The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional activator. Oncogene 1995; 11: 545 – 552
47. Eccles M. R., Wallis L. J., Fidler A. E., Spurr N. K., Goodfellow P. J., Reeve A. E. Expression of the PAX-2 gene in human fetal kidney and Wilms' tumor. Cell Grow Diff 1992; 3: 279 – 289
48. Kozmik Z., Sure U., Ruedi D., Busslinger M., Aguzzi A. Deregulated expression of PAX-5 in medulloblastoma. Proc Natl Acad Sci USA 1995; 92: 5709 – 5713
49. Wakatsuki Y., Neurath M. E, Max E. E., Strober W. The B cell-specific transcription factor BSAP regulates B cell proliferation. J Exp Med 1994; 179: 1099 – 1108
50. Usui T., Wakatsuki Y., Matsunaga Y., Kaneko S., Kosek H., Kita T. Overexpression of B cell-specific activator protein (BSAP/Pax-5) in a late B cell is sufficient to suppress differentiation to an Ig high producer cell with plasma cell phenotype. J Immunol 1997; 158 (7) 3197 – 3204
51. Stuart E. T., Haffner R., Oren M., Grass P. Loss of p53 function through PAX-mediated transcriptional repression. EMBO J 1995; 14: 5638 – 5645